List of investigational antipsychotics
This is a list of investigational antipsychotics, or antipsychotics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
This list was last comprehensively updated in December 2017. It is likely to become outdated with time.
Receptor modulators
[edit]Monoamine receptor modulators
[edit]- Brilaroxazine (RP5063; oxaripiprazole) – atypical antipsychotic (D2/3/4 and 5-HT1A partial agonist and 5-HT2A/2B/7 antagonist)[1]
- FKF-02SC (TGOF-02N) – atypical antipsychotic (D2 and 5-HT2A receptor antagonist, other actions)[2]
- Masupirdine (SUVN-502) – 5-HT6 receptor antagonist[3]
- N-Methylamisulpride (LB-102) – D2,3, 5-HT7, receptor antagonist (methylated version of amisulpride)[4]
- Ralmitaront (RG-7906, RO-6889450) – TAAR1 agonist[5]
- Ulotaront (SEP-856, SEP-363856) – 5-HT1A receptor and TAAR1 agonist[6]
- Usmarapride (SUVN-D4010) – 5-HT4 receptor partial agonist[7]
Glutamate receptor modulators
[edit]- Pomaglumetad methionil (DB-103, LY-2140023, LY-2812223) – mGluR2 and mGluR3 agonist[8]
Acetylcholine receptor modulators
[edit]- Emraclidine (CVL-231) – M4 muscarinic acetylcholine receptor positive allosteric modulator.[9]
- ML-007 – M1 and M4 muscarinic acetylcholine receptor agonist.[10]
- NBI-1117568 (HTL 0016878) – M4 muscarinic acetylcholine receptor agonist.[11]
- NS-136 – M4 muscarinic acetylcholine receptor positive allosteric modulator[12]
Cannabinoid receptor modulators
[edit]- Cannabidiol (CBD; GW-42003, GWP-42003, GWP-42003-P, ECP-012A; Arvisol, Epidiolex) – cannabinoid receptor modulator, antioxidant, other actions[13][14]
Other/mixed receptor modulators
[edit]- CVN766 – Orexin receptor type 1 antagonist[15]
- Deudextromethorphan (d-DM; AVP-786, CTP-786) – σ1 receptor agonist, serotonin–norepinephrine reuptake inhibitor, uncompetitive NMDA receptor antagonist, muscarinic acetylcholine receptor agonist, other actions[16][17]
- Roluperidone (CYR-101, MIN-101, MT-210) – 5-HT2A and σ2 receptor antagonist[18]
- TAK-041 (NBI 1065846) – GPR139 receptor agonist[19]
Enzyme inhibitors
[edit]- Luvadaxistat (NBI 1065844, TAK-831) – D-amino acid oxidase inhibitor.[20]
- MK-8189 – phosphodiesterase 10A inhibitor.[21]
- Osoresnontrine (BI-409306, SUB-166499) – phosphodiesterase 9A inhibitor[22]
- Sodium benzoate (SND-11, SND-12, SND-13, SND-14; Clozaben, NaBen) – D-amino acid oxidase inhibitor[23]
Ion channel modulators
[edit]Others
[edit]- TS-134 (TS-1341) – undefined mechanism of action[25]
- Kratom – Has shown antipsychotic-like effects on par with haloperidol in animal testing[26][27]
See also
[edit]References
[edit]- ^ "Brilaroxazine - Reviva Biopharmaceuticals - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ "FKF 02SC - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ "Masupirdine - Suven Life Sciences - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ "N-methyl amisulpride - LB pharmaceuticals - AdisInsight". adisinsight.springer.com. Retrieved 2023-02-21.
- ^ "Ralmitaront - AdisInsight". adisinsight.springer.com. Springer. Retrieved 10 July 2021.
- ^ "SEP 363856 - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ "SUVN D4010 - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ "Pomaglumetad methionil - Denovo Biopharma/Eli Lilly and Company - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ "Emraclidine - Cerevel Therapeutics - AdisInsight". adisinsight.springer.com. Retrieved 2023-02-15.
- ^ "ML 007 - AdisInsight". adisinsight.springer.com. Retrieved 2023-02-15.
- ^ "HTL 0016878 - AdisInsight". adisinsight.springer.com. Retrieved 2023-02-21.
- ^ "NS 136". AdisInsight. 15 May 2024. Retrieved 20 October 2024.
- ^ "Cannabidiol - GW Pharmaceuticals - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ "Cannabidiol - Echo Pharmaceuticals - AdisInsight". adisinsight.springer.com. Retrieved 14 February 2020.
- ^ "CVN 766 - AdisInsight". adisinsight.springer.com. Retrieved 2023-02-19.
- ^ "Deudextromethorphan - Avanir Pharmaceuticals - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ Nguyen, Linda; Thomas, Kelan L.; Lucke-Wold, Brandon P.; Cavendish, John Z.; Crowe, Molly S.; Matsumoto, Rae R. (March 2016). "Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders". Pharmacology & Therapeutics. 159: 1–22. doi:10.1016/j.pharmthera.2016.01.016. ISSN 1879-016X. PMID 26826604.
- ^ "Roluperidone - Minerva Neurosciences - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ "TAK 041 - AdisInsight". adisinsight.springer.com. Retrieved 2023-02-21.
- ^ "Luvadaxistat - Takeda - AdisInsight". adisinsight.springer.com. Retrieved 2023-02-21.
- ^ "MK 8189 - AdisInsight". adisinsight.springer.com. Retrieved 2023-02-21.
- ^ "BI 409306 - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ "Sodium benzoate - SyneuRx - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ "Evenamide - Newron Pharmaceuticals - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ "TS 134 - AdisInsight". adisinsight.springer.com. Springer. Retrieved 14 February 2020.
- ^ Vijeepallam, K.; Pandy, V.; Kunasegaran, T.; Murugan, D. D.; Naidu, M. (2016). "Mitragyna speciosa Leaf Extract Exhibits Antipsychotic-Like Effect with the Potential to Alleviate Positive and Negative Symptoms of Psychosis in Mice". Frontiers in Pharmacology. 7: 464. doi:10.3389/fphar.2016.00464. PMC 5138496. PMID 27999544.
- ^ Johnson, L. E.; Balyan, L.; Magdalany, A.; Saeed, F.; Salinas, R.; Wallace, S.; Veltri, C. A.; Swogger, M. T.; Walsh, Z.; Grundmann, O. (2020). "The Potential for Kratom as an Antidepressant and Antipsychotic". The Yale Journal of Biology and Medicine. 93 (2): 283–289. PMC 7309668. PMID 32607089.